The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy

Recruiting Observational Study
Lung Cancer
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
500 (estimated)
Sponsor
China-Japan Friendship Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Definitive radiotherapy is one of the important methods for inoperable locally advanced lung cancer. The recommended dose for definitive radiotherapy is 60-70Gy, and the optimal dose is still uncertain. Residual lesion after radiotherapy is a risk factor for recurrence. High doses to targeted tumor areas can effectively improve the local control rate, while minimizing toxic side effects. The regre…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years old; 2. Stage II-III lung cancer with a clear pathological diagnosis report or medical record, not undergoing surgery before radiotherapy; 3. The primary lung lesion received definitive radiotherapy (defined as conventional fractionation radiotherapy with dose ≥…
Contacts

Guangying Zhu, M.D.

+86 010-84205380

zryyfa@163.com

CONTACT